Review

You have free access to this content

Immunologic Biomarkers: Catalysts for Translational Advances in Autoimmune Diabetes

1. Simi T. Ahmed¹, 
2. Eitan Akirav^2,†, 
3. Elizabeth Bradshaw^3,†, 
4. Jane Buckner^4,†, 
5. Eoin McKinney^5,†, 
6. Francisco J. Quintana^3,†,
7. Frank Waldron-Lynch^5,†, 
8. Jerry Nepom^4,†

DOI: 10.1111/cei.12063

© 2013 British Society for Immunology, Clinical and Experimental Immunology

Issue

Clinical & Experimental Immunology

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Additional Information(Show All)

Author InformationPublication History

1. ^†
   ^#These authors contributed equally to the manuscript.
2. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/cei.12063

   
   

   • Abstract
   • Cited By

   Get PDF (362K)

   Abstract

   In a recent workshop organized by the Juvenile Diabetes Research Foundation (JDRF) focused on the “Identification and Utilization of Robust Biomarkers in Type1 Diabetes”, leaders in the field of Type 1 diabetes (T1D)/autoimmunity and assay technology came together from academia, government and industry to assess the current state of the field, evaluate available resources/technologies, and identify gaps that need to be filled for moving the field of T1D research forward. The highlights of this workshop are discussed in this article, as well as the proposal for a larger, planned consortium effort, incorporating a JDRF Biomarker Core, to foster collaboration and accelerate progress in this critically needed area of T1D research.

   Get PDF (362K)